On December 12, Janssen announced the 48-week results of the head-to-head PKECLIPSE Phase III study of Tremfya (guselkumab) and Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis. In the Tremfya treatment group, the psoriasis area and severity index improved by more than 90% (PASI 90, primary… Continue Reading Johnson & Johnson’s new psoriasis PK wins, Novartis Cosentyx is counterattacked

  Genentech announced on December 6 that the FDA approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) for first-line treatment of metastatic non-squamous non-small cell lung cancer without EGFR or ALK mutations. . The approval is based on data from a multicenter, open-label, randomized, controlled… Continue Reading Roche PD-L1 first-line therapy for lung cancer

  Almost everyone did not notice that the cumulative market value of the three CRISPR listed companies tripled between June 2017 and June 2018, with a cumulative market value of nearly $6 billion. However, in the past six months, the market value of these three companies has fallen by nearly… Continue Reading Progress of the latest clinical trials of 3 CRISPR listed companies

  On November 23, the application for the Bayer prostate cancer new drug Xofigo (Rainium Chloride [223Ra] Injection) was officially accepted by CDE. Xofigo was first approved by the FDA on May 15, 2013 for the treatment of advanced bone metastases in castration-resistant prostate cancer. In the Phase 3 ALSYMPCA… Continue Reading Bayer prostate cancer new drug Xofigo applied for listing in China

Recently, American company Moderna submitted an IPO application S-1 to the US Securities and Exchange Commission, and plans to conduct a $500 million initial public offering on the Nasdaq Global Select. This also means that the news that Moderna will be listed in Hong Kong has been rumored. Although there… Continue Reading Moderna’s $500 million record IPO

  According to AbbVie’s previous patent litigation settlement agreement with Amgen and Samsung Bioepis, Humira’s biological analogues officially landed on the European market on October 16, 2018. In addition, European listing applications for Humira analogues, including Boehringer Ingelheim, Mylan, etc., are also in the EMA approval process. In response to… Continue Reading Humira bio analogs officially launched, AbbVie Europe cuts prices by 80%

  Bloomberg reported that Jay Bradner, head of Novartis R&D, revealed that after conducting a comprehensive pipeline asset assessment, Novartis has reduced its number of new drug projects from 430 to 340. Jay Bradner Bradner said: “We have a good understanding of the scientific foundation behind these 90 projects. Although… Continue Reading Novartis R&D begins to slim down, 90 new drug projects will be shelved or transferred

  On October 5, the FDA approved a supplemental application for Merck’s Gardasil 9 (9-valent recombinant human papillomavirus vaccine, HPV vaccine) for vaccination for women aged 27-45 and male adults. Prior to this, Gardasil 9 was intended for women aged 9-26 or male adolescents and adults, and the FDA did… Continue Reading FDA approves cervical cancer vaccine Gardasil 9 expanded for use: available to women and men aged 27-45

  Clinical outcomes are one of the gold standards for assessing the availability of new drugs, which often determines their reputation after listing. As a “living drug”, CAR-T therapy is to collect blood from patients, transport blood samples to the production GMP center, extract and purify T cells, lentivirus transfection… Continue Reading CAR-T production, outsourcing or building your own factory?

Busy week for BCMA. On Monday, the FDA granted Gilead/Kite a CATMA-recognized CAR-T therapy orphan drug. At the same time, at the myeloma 2018 meeting, Amgen also announced early clinical data on its TBMA-targeted BiTE drug AMG-420. Affected by the data, the shares of Bluebird Bio and Celgene fell on… Continue Reading CAR-T confronts double antibodies, and Amgen’s drugs targeting BCMA may be a huge threat to Bluebird